Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment
Read original at benzingaAstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.
Read original at zacks-investment-researchAstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.
Read original at zacks-investment-researchAstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.
Read original at benzinga